Discover
PMCB
PharmaCyte Biotech, Inc.
0.61
1 x 0.51
38 x 0.65
bid
ask
-
0.01
2.12%
50 @ 04:00 PM
0.60 -0.01 (1.66%)
| Ytd | -15.73% | |
| 1y | -38.99% |
0.60
day range
0.63
0.60
52 week range
1.51
| Open | 0.62 | Prev Close | 0.62 | Low | 0.60 | High | 0.63 | Mkt Cap | 4.15M |
| Vol | 166.34K | Avg Vol | 172.45K | EPS | 1.45 | P/E | 0.42 | Forward P/E | -4.21 |
| Beta | 0.53 | Short Ratio | 1.09 | Inst. Own | 13.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.75 | 200-d Avg | 0.80 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 2.12M | ||
| Research and Development Expense | 93.11K | ||
| Selling, General and Administrative Expense | 2.02M | ||
| Operating Income | -2.12M | ||
| Net Income | 746.86K | ||
| Net Income Common Stock | -1.56M | ||
| Net Income Common Stock (USD) | -1.56M | ||
| Consolidated Income | 746.86K | ||
| Earnings per Basic Share | -0.17 | ||
| Earnings per Basic Share (USD) | -0.17 | ||
| Earnings per Diluted Share | -0.17 | ||
| Earning Before Interest & Taxes (EBIT) | 746.86K | ||
| Earning Before Interest & Taxes (USD) | 746.86K | ||
| Preferred Dividends Income Statement Impact | 2.30M | ||
| Weighted Average Shares | 9.26M | ||
| Weighted Average Shares Diluted | 9.26M | ||
| Balance Sheet | |||
| Cash and Equivalents | 20.17M | ||
| Cash and Equivalents (USD) | 20.17M | ||
| Investments | 33.99M | ||
| Investments Current | 372.25K | ||
| Investments Non-Current | 33.62M | ||
| Current Assets | 20.70M | ||
| Total Assets | 55.87M | ||
| Current Liabilities | 1.68M | ||
| Total Liabilities | 16.47M | ||
| Accumulated Retained Earnings (Deficit) | -100.00M | ||
| Accumulated Other Comprehensive Income | -21.54K | ||
| Shareholders Equity | 38.11M | ||
| Shareholders Equity (USD) | 38.11M | ||
| Assets Non-Current | 35.18M | ||
| Goodwill and Intangible Assets | 1.55M | ||
| Liabilities Non-Current | 14.79M | ||
| Trade and Non-Trade Payables | 1.20M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 543.78K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 4.76M | ||
| Issuance (Purchase) of Equity Shares | -401.62K | ||
| Net Cash Flow from Investing | 5.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 5.00M | ||
| Net Cash Flow from Operations | -786.85K | ||
| Effect of Exchange Rate Changes on Cash | 2.59K | ||
| Share Based Compensation | 952.99K | ||